CONMED (NASDAQ:CNMD) will be releasing its earnings data after the market closes on Thursday, November 1st. Analysts expect CONMED to post earnings of $0.45 per share for the quarter. CONMED has set its FY18 guidance at $2.15-2.20 EPS.
CONMED (NASDAQ:CNMD) last announced its earnings results on Wednesday, August 1st. The medical technology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.01. CONMED had a return on equity of 9.51% and a net margin of 8.85%. The firm had revenue of $212.80 million during the quarter, compared to analyst estimates of $207.12 million. During the same period last year, the firm posted $0.41 EPS. The business’s revenue was up 7.9% compared to the same quarter last year. On average, analysts expect CONMED to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of CONMED stock opened at $68.47 on Tuesday. CONMED has a 1 year low of $49.09 and a 1 year high of $83.49. The firm has a market cap of $1.94 billion, a PE ratio of 36.23, a price-to-earnings-growth ratio of 2.77 and a beta of 0.51. The company has a quick ratio of 1.15, a current ratio of 1.97 and a debt-to-equity ratio of 0.67.
In other CONMED news, EVP Peter K. Shagory sold 2,500 shares of the firm’s stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $80.00, for a total value of $200,000.00. Following the completion of the transaction, the executive vice president now owns 3,655 shares in the company, valued at approximately $292,400. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Stanley W. Peters III sold 1,500 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $80.43, for a total value of $120,645.00. Following the completion of the transaction, the vice president now owns 1,496 shares of the company’s stock, valued at approximately $120,323.28. The disclosure for this sale can be found here. In the last three months, insiders sold 8,000 shares of company stock valued at $639,565. 3.13% of the stock is currently owned by insiders.
Several brokerages have recently issued reports on CNMD. Zacks Investment Research raised CONMED from a “sell” rating to a “hold” rating in a research report on Wednesday, October 3rd. Leerink Swann lifted their price objective on CONMED from $76.00 to $81.00 and gave the stock a “market perform” rating in a report on Thursday, August 30th. BidaskClub lowered CONMED from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 11th. Finally, Needham & Company LLC lifted their price objective on CONMED from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $74.40.
CONMED Company Profile
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.
See Also: Using the New Google Finance Tool
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.